Skip to main content
. 2020 Nov 2;106(7):674–679. doi: 10.1136/archdischild-2020-319040

Figure 2.

Figure 2

Median age in years at MPS I diagnosis by year interval for individuals with severe (blue) or attenuated (red) MPS I receiving ERT as primary therapy. Global distribution is shown in panel (A). Regional distributions are shown for North America (B) and Europe (C). Individual medians are shown at the base of each bar and individual n’s are shown above the bars. ERT, enzyme replacement therapy; MPS I, mucopolysaccharidosis type I.